174 related articles for article (PubMed ID: 26889658)
1. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z; Harris PK; Karmakar P; Kim T; Owusu BY; Wildman SA; Klampfer L; Janetka JW
ChemMedChem; 2016 Mar; 11(6):585-99. PubMed ID: 26889658
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
3. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.
Damalanka VC; Wildman SA; Janetka JW
Medchemcomm; 2019 Sep; 10(9):1646-1655. PubMed ID: 31803403
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Han Z; Harris PK; Jones DE; Chugani R; Kim T; Agarwal M; Shen W; Wildman SA; Janetka JW
ACS Med Chem Lett; 2014 Nov; 5(11):1219-24. PubMed ID: 25408834
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
7. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
8. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Kwon H; Kim Y; Park K; Choi SA; Son SH; Byun Y
Bioorg Med Chem Lett; 2016 Jan; 26(2):310-314. PubMed ID: 26711145
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D
Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933
[TBL] [Abstract][Full Text] [Related]
11. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Beckmann AM; Gilberg E; Gattner S; Huang TL; Vanden Eynde JJ; Mayence A; Bajorath J; Stirnberg M; Gütschow M
Bioorg Med Chem Lett; 2016 Aug; 26(15):3741-5. PubMed ID: 27287367
[TBL] [Abstract][Full Text] [Related]
14. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
15. Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.
Maiwald A; Hammami M; Wagner S; Heine A; Klebe G; Steinmetzer T
J Enzyme Inhib Med Chem; 2016; 31(sup1):89-97. PubMed ID: 27168215
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract][Full Text] [Related]
17. Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
Damalanka VC; Voss JJLP; Mahoney MW; Primeau T; Li S; Klampfer L; Janetka JW
J Med Chem; 2021 Dec; 64(24):18158-18174. PubMed ID: 34902246
[TBL] [Abstract][Full Text] [Related]
18. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
19. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors.
Banke IJ; Arlt MJ; Pennington C; Kopitz C; Steinmetzer T; Schweinitz A; Gansbacher B; Quigley JP; Edwards DR; Stürzebecher J; Krüger A
Biol Chem; 2003; 384(10-11):1515-25. PubMed ID: 14669995
[TBL] [Abstract][Full Text] [Related]
20. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
